These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825 [TBL] [Abstract][Full Text] [Related]
3. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869 [TBL] [Abstract][Full Text] [Related]
4. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192 [TBL] [Abstract][Full Text] [Related]
5. MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial. Levallet G; Dubois F; Fouret P; Antoine M; Brosseau S; Bergot E; Beau-Faller M; Gounant V; Brambilla E; Debieuvre D; Molinier O; Galateau-Sallé F; Mazieres J; Quoix E; Pujol JL; Moro-Sibilot D; Langlais A; Morin F; Westeel V; Zalcman G Oncotarget; 2017 Jan; 8(3):4313-4329. PubMed ID: 28008145 [TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135 [TBL] [Abstract][Full Text] [Related]
7. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192 [TBL] [Abstract][Full Text] [Related]
8. The role of DNA repair pathways in cisplatin resistant lung cancer. O'Grady S; Finn SP; Cuffe S; Richard DJ; O'Byrne KJ; Barr MP Cancer Treat Rev; 2014 Dec; 40(10):1161-70. PubMed ID: 25458603 [TBL] [Abstract][Full Text] [Related]
10. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Felip E; Rosell R Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733 [TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors: an interesting pathway also for non-small cell lung cancer? Levra MG; Olaussen KA; Novello S; Soria JC Curr Pharm Des; 2014; 20(24):3875-82. PubMed ID: 24191958 [TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701 [TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586 [TBL] [Abstract][Full Text] [Related]
14. BRCA1 Mutation: A Predictive Marker for Radiation Therapy? Kan C; Zhang J Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):281-93. PubMed ID: 26383678 [TBL] [Abstract][Full Text] [Related]
15. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Wachters FM; Wong LS; Timens W; Kampinga HH; Groen HJ Lung Cancer; 2005 Nov; 50(2):211-9. PubMed ID: 16169122 [TBL] [Abstract][Full Text] [Related]
16. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479 [TBL] [Abstract][Full Text] [Related]
17. Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality. Wang X; Liu L; Montagna C; Ried T; Deng CX Cell Death Differ; 2007 May; 14(5):924-31. PubMed ID: 17318223 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034 [TBL] [Abstract][Full Text] [Related]
19. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915 [TBL] [Abstract][Full Text] [Related]
20. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]